Pharma large Sanofi continues to modernise with branding which displays its dedication to social accountability and sustainability
Sanofi has revealed a brand new company model which helps the modernisation and transformation that the corporate launched in December 2019.
The brand new emblem goals to symbolize Sanofi’s ‘renewed function and visions for the longer term’ and the corporate has acknowledged that sustainability and social accountability lies on the coronary heart of these ambitions. With its new model, Sanofi pledges to carry its numerous historical past collectively in a single frequent identification, for the primary time.
Paul Hudson, CEO of Sanofi, defined the hanging model change: “As we method the half century mark of our firm’s existence, we now have undertaken an important transformation and modernisation in our historical past. In 2019, we launched our Play to Win technique, which focuses on making use of our platform for innovation to supply first and best-in-class remedies and vaccines. Our new model is a pure and essential subsequent step on this journey and represents the built-in method during which the corporate will work to realize our shared ambition to rework the follow of medication.”
Josep Catllà, head of Company Affairs at Sanofi, was equally excited by the rebooted identification. He mentioned: “With our new model, we now have sought to supply our individuals, our companions, sufferers and healthcare professionals with a transparent and powerful understanding of who we’re and what we’re set to realize,”
“Sanofi’s angle is humble, genuine–and a little bit bit unconventional too. We consider that our new model and emblem carve out a singular area within the healthcare trade that completely represents our new function to chase the miracles of science to enhance individuals’s lives,” he added.
Over the past 50 years, Sanofi has established itself as a various healthcare chief with a presence all through the world. The corporate’s pipeline consists of an enormous array of medicines for therapeutic areas reminiscent of oncology, immune-inflammation, uncommon illnesses and neurology.
Presently, Sanofi focuses on creating medication and vaccines with the best potential to enhance, lengthen and remodel the lives of sufferers. As of late September 2021, the medication and vaccines of Sanofi’s R&D pipeline included 82 tasks, 34 of that are in section 3, or have been submitted to regulatory authorities for approval.